Literature DB >> 29303931

Prognostic Significance of omental Disease and the Role of Omental Sampling in Patients With Uterine Carcinosarcoma.

Malcolm Strachan Ross, Esther Elishaev, Jessica Layne Berger, Joseph Leo Kelley, Sarah Elizabeth Taylor.   

Abstract

OBJECTIVES: Uterine carcinosarcomas are an aggressive and rare form of endometrial cancer. Omentectomy is not part of routine staging, but biopsy is often done because omental disease is a known poor prognostic indicator. We sought to define the role of routine omental sampling during surgical staging. METHODS/MATERIALS: Patients who underwent staging for uterine carcinosarcoma at our institution from January 2000 to December 2013 were identified. Clinical and pathological data were abstracted. Univariate and multivariable Cox proportional hazard regression analysis was used to identify significant predictors of progression-free (PFS) and overall survival (OS). Logistic regression was used to identify predictors of omental disease.
RESULTS: We identified 153 patients. The median age was 65 years (range, 40-87 years), and 88.9% were Caucasian. Omental sampling was performed in 106 (69.3%) patients. Of these, 17(16%) had pathologically confirmed omental disease, and 6 (35.3%) with microscopic disease. On multivariable analysis, tumor size (P = 0.024) and postoperative radiation (P = 0.041) were significant predictors of progression-free survival, and omental disease (P = 0.002), residual disease (P = 0.03), and tumor size (P = 0.025) were significant predictors of OS. Median OS was 11.4 versus 128.7 months for those who did and did not have omental disease, respectively (P <0.001). The median OS for those who had omental sampling (127.7 months) versus those who did not (71.3 months) was not significantly different (P = 0.7432).
CONCLUSIONS: Although survival was not significantly different between those who did and did not have omental sampling, omental disease had a significant impact on survival. Of those with omental disease, 35% had microscopic disease that could be missed if routine biopsy is not performed, suggesting a role for routine omental sampling.

Entities:  

Mesh:

Year:  2018        PMID: 29303931     DOI: 10.1097/IGC.0000000000001176

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

1.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

2.  The role of omentectomy in the surgical treatment of uterine serous carcinoma.

Authors:  Ming Chen; Peng Guo; Jifan Tan; Duo Liu; Shuzhong Yao
Journal:  Eur J Obstet Gynecol Reprod Biol X       Date:  2019-07-10

3.  Role of minimally invasive surgery versus open approach in patients with early-stage uterine carcinosarcomas: a retrospective multicentric study.

Authors:  Giacomo Corrado; Francesca Ciccarone; Francesco Cosentino; Francesco Legge; Andrea Rosati; Martina Arcieri; Luigi Carlo Turco; Camilla Certelli; Alex Federico; Enrico Vizza; Francesco Fanfani; Giovanni Scambia; Gabriella Ferrandina
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-03       Impact factor: 4.553

4.  Uterine carcinosarcoma: A 10-year single institution experience.

Authors:  Leana Terblanche; Matthys H Botha
Journal:  PLoS One       Date:  2022-07-21       Impact factor: 3.752

5.  Is omentectomy necessary in the treatment of benign or malignant abdominal pathologies? A systematic review.

Authors:  Arif Atay; Osman Nuri Dilek
Journal:  World J Gastrointest Surg       Date:  2021-11-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.